



CHANGING THE COURSE OF
HUMAN HEALTH THROUGH BOLD
PURSUITS IN SCIENCE



Leerink Partners Global Healthcare Conference

February 15, 2018



Forward-Looking Statements and Adjusted Financial Information

This presentation contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook,” “targets” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

In addition to unaudited financial information prepared in accordance with U.S. GAAP, this presentation also contains adjusted financial measures. Further information relevant to the interpretation of adjusted financial measures, and reconciliations of these adjusted financial measures to the most comparable GAAP measures, may be found in the Appendix and on our website at www.Celgene.com in the “Investor Relations” section.






Additional Information on the Tender Offer

While the tender offer for Juno shares has commenced, the description contained herein is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any shares of Juno. Celgene's Tender Offer Statement on Schedule TO containing an offer to purchase, a form of letter of transmittal and other documents relating to the tender offer, and Juno's Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer are on file with the Securities and Exchange Commission (SEC). These documents have been sent to the stockholders of Juno.

THESE DOCUMENTS, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, CONTAIN IMPORTANT INFORMATION ABOUT THE TENDER OFFER AND JUNO STOCKHOLDERS ARE URGED TO READ THEM CAREFULLY. STOCKHOLDERS OF JUNO CAN OBTAIN A FREE COPY OF THESE DOCUMENTS AND OTHER DOCUMENTS FILED BY JUNO AND CELGENE WITH THE SEC AT THE WEBSITE MAINTAINED BY THE SEC AT WWW.SEC.GOV.



Our Mission and Vision



*Celgene is building a preeminent global biopharmaceutical company focused on the discovery, development and commercialization of **innovative therapies** for patients with cancer, immune-inflammatory, and other unmet medical needs*



Deploying a Strategy to Grow Through 2020 and Beyond



Strong Volume-Driven Growth Expected in 2018



*Adjusted financial measure

Note: Calculation of Y/Y growth is from preliminary and unaudited 2017 measurements to the mid-point of the range.

2018 guidance does not include the impact of our recently announced pending acquisition of Juno Therapeutics Inc., which is expected to be dilutive to adjusted diluted EPS in 2018 by approximately \$0.50.

Accelerating Diversification by Advancing Medicines to Transform the Treatment of Diseases



HEMATOLOGY & ONCOLOGY

Multiple Myeloma

60K
Incidence


\$27B
Market Opportunity



Non-Hodgkin Lymphoma

90K
Incidence


\$17B
Market Opportunity



Myeloid Diseases

65K
Incidence

\$5B
Market Opportunity




INFLAMMATION & IMMUNOLOGY

Psoriasis / Psoriatic Arthritis

5M
Prevalence

\$26B
Market Opportunity



Multiple Sclerosis

650K
Prevalence

\$23B
Market Opportunity



Inflammatory Bowel Disease

2.3M
Prevalence

\$21B
Market Opportunity



Source: Market size projections are for 2022 from Evaluate Pharma, December 2017 and Decision Resources Disease Landscape and Forecast; Epidemiology is for 2018 from Decision Resources Disease Landscape and Forecast, Kantar Health CancerMPact database and Putnam Associates

Building a Pipeline of Next-Generation Growth Drivers



Internal Innovation Engine

Advancing 8 New Programs into the Clinic

<p>CC-92480</p> <ul style="list-style-type: none"> Next-Gen CELMoD® Ph I for MM 	<p>CC-93269</p> <ul style="list-style-type: none"> BCMA T cell engager Ph I for MM
<p>CC-90010</p> <ul style="list-style-type: none"> BET inhibitor Ph I for solid tumors 	<p>AG-270</p> <ul style="list-style-type: none"> Mat2A inhibitor Ph I for solid tumors
<p>bb21217</p> <ul style="list-style-type: none"> BCMA CAR T Ph I for MM 	<p>GEM333</p> <ul style="list-style-type: none"> CD3xCD33 bispecific Ph I for AML
<p>MSC-1</p> <ul style="list-style-type: none"> Anti-LIF1 MAb Ph I for solid tumors 	<p>RPC8844</p> <ul style="list-style-type: none"> GLP-1R modulator Targeted for NASH

■ Protein Homeostasis ■ Epigenetics
■ Inflammation & Immunology ■ Immuno-Oncology



Announced BD Transactions

<p>BGB-A317 Anti-PD-1 mAb</p>	<ul style="list-style-type: none"> Demonstrated anti-tumor activity in a range of solid tumors with an acceptable safety profile to support continued development Biomarker-driven pivotal program planned in multiple tumor types and lines of therapy Exploring combinatorial potential with existing drug classes and emerging I/O agents
<p>Fedratinib JAK2 kinase inhibitor</p>	<ul style="list-style-type: none"> Myelofibrosis clinical program completed to date: <ul style="list-style-type: none"> Ph III trial in treatment-naïve patients Ph II trial in patients resistant or intolerant to Jakafi® NDA submission for myelofibrosis planned in mid-2018 Accelerate ongoing myelofibrosis program with luspatercept, in addition to early Protein Homeostasis and Epigenetic programs
<p>JCAR017 CD19 CAR T</p>	<ul style="list-style-type: none"> JCAR017 clinical data supports a potentially best-in class profile providing an anchor therapy in NHL Pivotal program in DLBCL under way Broad clinical development plan to maximize clinical and commercial potential of JCAR017

Late-stage Pipeline with Potential to Add Over \$16B in Incremental Peak Revenue Through 2030



Delivering Industry-Leading Growth Through 2020...

Revenue


14.5%
CAGR

Adj. Diluted EPS

~19%
CAGR

...And Positioned to Grow Beyond 2020

Expected to Launch Ten Potential Blockbusters



Current Estimate of Peak Sales Potential:



Note: CAGR calculation is from preliminary and unaudited 2017 measurements to the midpoint of the 2020 total revenue range
 \$16 billion represents sum of individual potential peak sales for each illustrated product, which may not coincide. Peak sales for each product may not occur during illustrated timeframe. Graph is not to scale.

Transactions for Impact Biomedicines and Juno Therapeutics, Inc., subject to completion